First case of bacteremia caused by Helicobacter cinaedi in a patient with liver cirrhosis: a case report and literature review

Clinical Journal of Gastroenterology
Kenya KamimuraShuji Terai

Abstract

Patients with liver cirrhosis are known to be immunocompromised hosts due to the dysfunction of the cellular and humoral immune systems, allowing easier bacterial translocation from the intestine to the systemic circulation via the portal vein. Sepsis can often be seen in these patients; however, approximately 10 % of patients show negative results with the standard culture period (3-4 days) and their pathogens remain undiagnosed. Here we report the first case of a patient with liver cirrhosis diagnosed with bacteremia due to Helicobacter cinaedi after gastrointestinal symptoms and review 62 cases of H. cinaedi infection in patients with other diseases. The patient showed positive results for H. cinaedi after 10 days of culture. Administration of a carbapenem was effective and clinical symptoms recovered 20 days after admission. H. cinaedi is an enterohepatic bacterial species that causes bacteremia in immunocompromised patients. Due to the difficulty of detection, few cases have been reported to date and to the best of our knowledge, this is the first published case of bacteremia due to H. cinaedi infection in a patient with liver cirrhosis. Since bacteremia in patients with liver cirrhosis can result in fatality, we recommend...Continue Reading

References

Sep 1, 1984·Annals of Internal Medicine·J PasternakW E Stamm
Mar 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W J BurmanM L Wilson
Oct 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M P MammenT P Endy
Jan 1, 1996·Scandinavian Journal of Infectious Diseases·W TeeA Mijch
Jul 29, 2000·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·S LasryY Boussougant
Dec 24, 2003·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hinako MurakamiTakashi Takahashi
Jul 30, 2005·Scandinavian Journal of Infectious Diseases·Perry J J Van GenderenPieter L C Petit
May 25, 2006·BMC Infectious Diseases·Ilker UçkayVéronique Jacomo
Nov 3, 2006·Journal of Clinical Microbiology·Toshio KitamuraTakaaki Akaike
Jun 29, 2007·Journal of Clinical Microbiology·Tetsuya MatsumotoKeizo Yamaguchi
Dec 18, 2008·The Open Microbiology Journal·Helle HolstJens Jørgen Christensen
Nov 4, 2009·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Thierry GustotRichard Moreau
Aug 20, 2010·Internal Medicine·Koichiro MinauchiMasaya Mukai
Jun 19, 2012·The Turkish Journal of Gastroenterology : the Official Journal of Turkish Society of Gastroenterology·Toru Shizuma, Naoto Fukuyama
Nov 7, 2012·Annals of Laboratory Medicine·Soo-Kyung KimGi-Byoung Nam
Sep 18, 2013·Helicobacter·Bram FlahouShigeru Kamiya
Oct 10, 2013·Journal of Vascular Surgery·Yoshihiro SuematsuMitsuhiro Kawata
Oct 31, 2013·Journal of the Neurological Sciences·Atsuhiko SugiyamaSatoshi Kuwabara
Dec 18, 2013·Virulence·Christa A SchorrR Phillip Dellinger
Mar 13, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Thierry GustotUNKNOWN EPIC II Group of Investigators
Jul 16, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Yoshiaki KawamuraTakaaki Akaike
Aug 30, 2014·Helicobacter·Armelle MénardBram Flahou
Nov 19, 2014·BMC Infectious Diseases·Hanni BartelsVeronika Bättig
Jan 28, 2015·Médecine et maladies infectieuses·F MorelE Caumes

❮ Previous
Next ❯

Citations

Aug 18, 2016·Helicobacter·Chloë De WitteFreddy Haesebrouck
Mar 10, 2019·BMJ Case Reports·Koichiro LeeFutoshi Nakagami
Aug 3, 2017·Open Forum Infectious Diseases·Josué Pérez-SantiagoJoshua Fierer
Feb 23, 2019·Emerging Infectious Diseases·Tetsuya SuzukiNorio Ohmagari
Jun 22, 2021·Critical Reviews in Microbiology·Sofia Ochoa, Luis Collado

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.